N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study

Bibliographic Details
Main Authors:	Emberson, J, Armitage, J, Ng, L, Bowman, L, Parish, S, Collins, R, Group, HPSC
Format:	Conference item
Published:	2005

Similar Items

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
by: Emberson, J, et al.
Published: (2005)

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
by: Emberson, JR, et al.
Published: (2007)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
by: Heart Protection Study Collaborative Group
Published: (2002)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
by: Collins, R, et al.
Published: (2002)

MRC/BHF Heart Protection Study - Reply
by: Collins, R, et al.
Published: (2002)

Comments on the MRC/BHF Heart Protection Study - Authors' reply
by: Collins, R, et al.
Published: (2003)

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
by: Parish, S, et al.
Published: (2012)

The MRC/BHF Heart Protection Study: preliminary results.
by: Collins, R, et al.
Published: (2002)

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
by: Mihaylova, B, et al.
Published: (2005)

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
by: Armitage, J, et al.
Published: (2009)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
by: Bulbulia, R, et al.
Published: (2007)

Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
by: Mihaylova, B, et al.
Published: (2005)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
by: Bulbulia, R, et al.
Published: (2011)

MRC/BHF Heart Protection Study.
by: Vaughan, C, et al.
Published: (2002)

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
by: Mihaylova, B, et al.
Published: (2006)

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
by: Collins, R, et al.
Published: (2003)

Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials.
by: Armitage, J, et al.
Published: (2000)

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
by: Heart Protection Study Collaborative Group
Published: (2007)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
by: Collins, R, et al.
Published: (2004)

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].
by: Group, H
Published: (2005)

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]
Published: (2005-03-01)

20536. COMPLICACIONES NEUROLÓGICAS PARENQUIMATOSAS EN LA ENFERMEDAD DE BEHÇET
by: E. Estrada Palma, et al.
Published: (2024-11-01)

C-reactive protein in the Heart Protection Study - Authors' reply
by: Emberson, J, et al.
Published: (2011)

Assessing the impact sensitivity of explosives using the BHF-12A equipment
by: Rădeanu Cristian, et al.
Published: (2020-01-01)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
by: Hopewell, J, et al.
Published: (2011)

The MRC spine stabilization trial
by: Wilson-MacDonald, J, et al.
Published: (2008)

C-reactive protein in the Heart Protection Study Reply
by: Emberson, J, et al.
Published: (2011)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
by: Hopewell, J, et al.
Published: (2011)

Failure Investigation of Blank Holder Force (BHF) Control in The Outside Bracket For Front Seat
by: Rofan Yulian Romansyah, et al.
Published: (2023-06-01)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
by: Hopewell, J, et al.
Published: (2009)

Biomarkers of inflammation predict both vascular and non-vascular mortality in older men.
by: Clarke, R, et al.
Published: (2008)

Biomarkers of inflammation predict both vascular and non-vascular mortality in older men
by: Clarke, R, et al.
Published: (2008)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
by: J. M. Short, et al.
Published: (2023-09-01)

Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors.
by: Bowman, L, et al.
Published: (2007)

HYPERFINE INTERACTIONS, INCLUDING BHF[FRFE], STUDIED IN THE DECAY CHAIN OF RA-225 BY ALPHA-ANISOTROPY AND GAMMA-ANISOTROPY MEASUREMENTS
by: Lindroos, M, et al.
Published: (1992)

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
by: Hopewell, J, et al.
Published: (2011)

ANXIETY, FRACTURE RISK AND ADHERENCE TO TREATMENT: THE MRC SCOOP TRIAL
by: Harvey, N, et al.
Published: (2012)

The role of BNP testing in heart failure.
by: Doust, J, et al.
Published: (2006)

Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality
by: Parish, S, et al.
Published: (2010)

NT‐proBNP/BNP ratio for prognostication in European Caucasian patients enrolled in a heart failure prevention programme
by: Claire Sweeney, et al.
Published: (2021-12-01)